South Sudan Refocuses HIV, TB, Malaria Priorities in Grant Review Process

CCM Leads Partners in GC7 Review and Reprioritization Process

August 22, 2025
The CM Chairperson Dr. Jane Alphonse and Ministry of Health officials participated in the review meetings.

CCM Chairperson Dr. Jane Alphonse, Ministry of Health officials and partners during the review meetings.

UNDP South Sudan/ Michael Mubangizi

The South Sudan Country Coordinating Mechanism (CCM) has concluded the revision and reprioritization of the GC7 grant activities, focusing on safeguarding and enabling lifesaving HIV, TB and malaria interventions.

This exercise arose from the current challenging funding landscape for global health which necessitated reductions in GC7 grant allocations. Globally, the Global Fund reduced the GC7 allocations by $ 1.4 billion or 11% compared to 8.3% in South Sudan. The GC7 is now in its second year of implementation and will end in December 2026. The reprioritization was an opportunity to build momentum on integration, cost effectiveness and sustainability of HIV, TB and malaria programmes, and build a solid foundation for Grant Cycle 8.

As the Principal Recipient of the Global Fund’s HIV, TB and RSSH grants, UNDP actively participated in the GC7 review and reprioritization process.

As the Principal Recipient of the Global Fund’s HIV, TB and RSSH grants, UNDP actively participated in the GC7 review and reprioritization process.

UNDP South Sudan/ Michael Mubangizi

In South Sudan, CCM used a consultative process with all stakeholders to discuss the reprioritization. During one of the CCM consultative workshops held on 11 August 2025, and attended by the Ministry of Health, networks of PLHIV, UNDP and partners, the CCM Chairperson Dr. Jane Alphonse Juma said the collaborative approach was aimed at harmonizing positions, and promoting consensus and transparency, and to enlist, “Contribution from the stakeholders on the exercise to ensure that we don’t remove elements that are very essential for service delivery and life-saving interventions.”
Under the new arrangement, the GC7 grant allocation for South Sudan is $136,428,293, down from $143,954,945, indicating a $7,526,652 reduction principally deducted from the GC7 HIV and TB disease components managed by UNDP.

Participants at a CCM stakeholder consultation meeting

Participants at a CCM stakeholder consultation meeting

UNDP South Sudan

The $7,526,652 reduction was achieved with UNDP and all sub-recipients (MOH, SSAC, NEPWU, AMREF, CORDAID, UNFPA) contributing to the reduction. Key considerations and contributing factors to the savings include a major reduction in ARV prices, interest generated from funds held by UNDP and delayed activities which resulted in overall cost savings. 
Under the review exercise, some resources were reinvested or reprioritized, focusing on strengthening key-populations interventions, increasing PMTCT coverage, and the performance of key indicators on increasing capacity for TB diagnosis, viral load suppression, Early Infant Diagnosis (EID) and increasing ART enrollment for priority groups such as children/adolescents and the security or armed forces.

Driving results through collaborative engagement.

Driving results through collaborative engagement.

UNDP South Sudan

For the HIV and TB component, priority was put on increasing HIV case finding through high-yielding HIV testing approaches to achieve performance framework targets on ART coverage. During the reprioritization process, participants also called for strengthening of the malaria case funding and management interventions.